Tectonic Therapeutic
Biotechnology company developing therapeutics targeting G protein-coupled receptors (GPCRs) using structural biology and computational approaches to unlock previously undruggable GPCR targets for serious diseases.
Notes
Tectonic Therapeutic is a biotechnology company focused on developing therapeutics targeting G protein-coupled receptors (GPCRs). The company is headquartered in Cambridge, Massachusetts.
GPCRs are the largest family of membrane proteins in the human genome and are involved in nearly every physiological process. While GPCRs are the target of approximately 35% of all approved drugs, the majority of GPCRs remain undrugged due to technical challenges. Tectonic's approach combines:
- Advanced structural biology techniques
- Computational drug discovery
- Novel screening approaches
The company aims to unlock the therapeutic potential of previously undruggable GPCR targets for serious diseases.
Team
- Alise Reicin, M.D. - Chief Executive Officer
- LinkedIn: linkedin.com/in/alisereicin
Additional Research Findings
- Portfolio company of Polaris Partners
- Focus on GPCR-targeted therapeutics
- Structural biology-based drug discovery
- Cambridge, Massachusetts headquarters
- Founded in 2019
- Targeting undruggable GPCRs
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |